Hemispherx extends agreement with Armada Health Care

Hemispherx Biopharma, Inc. recently extended its agreement with Armada Health Care, LLC for two years for the sales and marketing of Alferon N Injection, its U.S. Food and Drug Administration-approved natural interferon.

The agreement now extends through Aug. 14, 2017.

“This extended agreement with Armada is gratifying,” Wayne Springate, senior vice president of operations for Hemispherx, said. “As leaders in the specialty pharmaceutical field, Armada is the ideal partner for the marketing and distribution of Alferon N Injection. Now with our upgrade work complete to include a high volume, state-of- the-art bioreactor for the manufacture of Alferon N Injection, we hope to be able to supply greater volumes of product to the market than in the past.”

Under the agreement, Hemispherx will manufacture and supply Alferon N Injection to physicians and patients through Armada's national network of specialty pharmacies. Armada has agreed to provide ongoing sales and marketing to support the product's relaunch.

"We have closely followed Hemispherx progress in its major upgrade of the Alferon manufacturing facility, and we are pleased that this is now complete and we can continue to work on preparing for the re-launch of Alferon N Injection,” Ryan Oligino, executive vice president of manufacturer relations for Armada Health Care, said. “As the only natural interferon approved in the U.S., we think Alferon N Injection has great potential in our market.”
Want to get notified whenever we write about Armada Health Care ?
Next time we write about Armada Health Care, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Armada Health Care 100 Campus Dr Florham Park, NJ 07932